OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Tabrecta"

In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell lung cancer ( NSCLC ) patients who were pretreated ( cohort 4 ) ...


Among patients with non–small-cell lung cancer ( NSCLC ), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib ( Tabrecta ), a selective inhibitor of t ...


MET exon 14 skipping mutations ( METex14 ) are seen in 3-4% of patients with non-small cell lung cancer ( METex14 NSCLC ) and are associated with poor outcomes. In the phase 2 GEOMETRY mono-1 stud ...